Showing all 5 results

390.00 Excl. VAT

BioNTech, CureVac, Moderna Therapeutics, Translate Bio…. These four biotech are the main state-of-the-art companies at the forefront in mRNA science. All of them are now developing mRNA-based vaccine candidates against SARS-CoV-2 and have reached the clinical stage. These programs could lead to short-term boosts for these companies’s shares. However, addressing epidemics is still a risky business. So far, it isn’t the [...]

990.00 Excl. VAT

RNA science is now translated into new therapies… Six RNA-based products are now approved More than one hundred candidates have reached the clinical stage…  “BRIEFING ON RNA TRIALS” provides you an accurate overview to explore the latest trials in this dynamic and rapidly evolving field FOUR REASONS TO BUY: Wishing to identify hot research topics in [...]

1,090.00 Excl. VAT

BioPharmAnalyses and Octopusyx BioConsulting are happy to announce the release of the second issue of their “BRIEFING ON CART-T CELLS TRIALS”   At least 5 reasons to buy “BRIEFING ON CART-T CELLS TRIALS” More than 140 new clinical trials registered between 01/01/2018 and 12/01/2019 For each clinical trial mentioned, a novel format enriched by relevant contextualisation [...]

Sale!
1,490.00 890.00 Excl. VAT

Our Briefing on RNA Trials provides you with an accurate overview to explore the latest trials in the RNA therapeutic area 86 pages detailing 101 clinical trials conducted in 44 countries -42 companies and academic institutions developing 78 RNA products (antisense oligonucleotides, RNAi/siRNA, microRNAs, mRNAs) -55 targets and 57 diseases in a wide range of [...]

390.00 Excl. VAT

CAR-T cells therapies are at the forefront of innovation in oncology. “BRIEFING ON CART-T CELLS TRIALS” provides you with an accurate overview to explore the latest trials in this hot and rapidly evolging field More than 20 diseases, mainly hematological cancers and solid tumors 47 trials and 33 sponsors in Asia, Europa and USA More [...]